BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2

[1]  Patrick W. Johnson,et al.  Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies , 2021, Cancer Cell.

[2]  F. Hernandez-Ilizaliturri,et al.  Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies , 2021, Blood.

[3]  R. Foà,et al.  Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. , 2021, The New England journal of medicine.

[4]  M. Grever,et al.  Hairy cell leukemia and COVID-19 adaptation of treatment guidelines , 2021, Leukemia.

[5]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia , 2021, Blood.

[6]  R. Gale,et al.  COVID-19 in persons with haematological cancers , 2020, Leukemia.

[7]  C. Dearden,et al.  Hairy Cell Leukaemia , 2020, Current Oncology Reports.

[8]  Jeffrey A Jones,et al.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. , 2017, Blood.

[9]  C. von Kalle,et al.  BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. , 2016, Blood.

[10]  M. Grever,et al.  Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. , 2015, The New England journal of medicine.

[11]  Kristina M. Ilieva,et al.  Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma , 2014, Molecular Cancer Therapeutics.

[12]  C. von Kalle,et al.  BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.

[13]  A. Tierens,et al.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. , 2011, Blood.

[14]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[15]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.